



Genocea Biosciences
Investor Relations Department
100 Acom Park Drive, 5th Floor
Cambridge, MA 02140
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: GNCA

Last Trade:	5.05
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	0.10 ↑ (+2.020%)
Day Range	4.94 - 5.10
52-Week Range	3.28 - 7.29
Volume	176,302

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 26, 2017

[Genocea Added to Russell 3000® and Russell 2000® Indices](#)

May 4, 2017

[Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes](#)

Apr 27, 2017

[Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET](#)

Apr 11, 2017

[Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes](#)

Mar 29, 2017

[Genocea to Present at the 16th Annual Needham Healthcare Conference](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 17, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)